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BACKGROUND Equations used to estimate kidney function for drug dosing rely on the assumption of
homeostasis to translate a single-point measurement of serum creatinine into clearance (CL). Our
objective was to rank order the performance of alternate kidney function equations as predictors of
drug CL in stable and unstable patients.
METHODS Data were extracted from medical records at a single center for all adult patients treated with
vancomycin over a 5-year period for population pharmacokinetic analysis. This analysis focused on
comparison of nine kidney function equations as covariates of vancomycin CL. Both body surface
area (BSA) indexed (ml/min/1.73 m2) and unindexed units (ml/min) of kidney function were tested,
as time-varying and time-invariant covariates of vancomycin CL.
RESULTS The final data set consisted of 2640 patients (62% male, 81% white) with 6628 concentration
measurements. The median (5th, 95th percentile) of measurements per patient, age, weight, body
mass index (BMI) was 2 (1, 7) concentrations, 61.5 (28, 83) years, 90.0 (56.7, 147) kg, and 30.0
(20.7, 48.0) kg/m2. Unstable kidney function was documented in 43.6% of patients, primarily as
acute kidney injury (AKI) on admission with improvement (19.4%) and AKI during the admission
(17.4%). Models based on time-varying kidney function estimates performed better than as time-in-
variant. Kidney function estimated by the Chen method was ranked higher than other estimation
methods.
CONCLUSIONS A time-varying kinetic estimated glomerular filtration rate method not indexed to BSA
was identified as the highest ranked covariate model of vancomycin CL.
KEY WORDS creatinine clearance, pharmacokinetics, unstable, glomerular filtration rate, antibiotic.
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One in seven individuals in the United States
are estimated to have chronic kidney disease
(CKD), which by definition develops over sev-
eral years and can progress to end-stage kidney
disease requiring dialysis or transplantation.1 In
contrast, acute kidney injury (AKI) is the sud-
den and temporary loss of kidney function
typically caused by shock, blood or fluid loss,
heart failure, nephrotoxic drugs, allergic reac-
tions, injuries, or major surgeries.2 Drug dosing
is adjusted for kidney function impairment typi-
cally when a significant portion (> 30%) of the
drug is eliminated in urine or if the safety pro-
file is altered.3 In clinical practice, accurate mea-
surement of kidney function through
administration of an exogenous biomarker is not
feasible and so requires estimation using endoge-
nous biomarkers such as serum creatinine and
cystatin C.3 Currently, the staging of CKD relies
on estimated glomerular filtration rate (eGFR),
while drug-dosing adjustment relies on either
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estimated creatinine clearance (eCrCL) or
eGFR.3 The eGFR and eCrCL equations for drug
dosing rely on a single-point measurement of
serum creatinine. The Modification of Diet in
Renal Disease (MDRD) equation and Chronic
Kidney Disease–Epidemiology (CKD-EPI) equa-
tions are the predominant eGFR methods in
adults.4–6 The Cockcroft-Gault (CG) equation is
the predominant method for eCrCL.7 Although
cystatin C improves the precision of kidney
function estimation with a modified CKD-EPI
function, it is not a widely accessible assay and
not included in any product label to guide drug
dosing.8
Translation of a single-point measurement of
serum creatinine into clearance (CL) is based on
the assumption of homeostasis, i.e., production
or systemic input of creatinine and the rate of
creatinine elimination is constant and equiva-
lent.9 A corollary to this estimation method
occurs with continuous infusion drug dosing,
where the rate of infusion (Ro) divided by the
steady-state concentration (Css) equals clearance
(CL). While this assumption may be reasonable
in healthy individuals and patients with CKD, it
is not for patients with AKI. Two key equations
that predate the CG equation, commonly known
as the Jelliffe method and Chiou method, were
developed in the 1970s and overcome this limi-
tation of single-point assessment by relying on a
moving-average method.10–12 These methods
rely on a creatinine volume of distribution esti-
mate of 0.6 L/kg based on ideal body weight
(IBW) and estimates of creatinine production
based on age, IBW, and gender. A kinetic eGFR
method (Chen equation) was introduced in
2013 that is also a moving-average method,
which transforms the CKD-EPI results with a
weighted maximum change in serum creatinine
of 1.5 mg/dl.13 Recently, use of these dynamic
models of kidney function have been shown to
be useful for drug-dosing considerations in
patients with unstable kidney function.14, 15 Five
decades have transpired since the original intro-
duction of the first eCrCL equation for patients
with unstable kidney function.10–12 The preva-
lence of obesity is projected to approach 50% in
the next decade, and life expectancy increased
by an average of 9 years in the United
States.16, 17 Serum creatinine assay methods
have also become traceable to an isotopic dilu-
tion mass spectrometry standard to reduce vari-
ability.6 Based on these changes in demography
and analytical methods, we undertook a reap-
praisal of existing kidney function equations as
covariates of drug CL. Our primary objective
was to compare eGFR and eCrCL as covariates
of drug CL to rank order the performance of
these equations in patients with stable and
unstable kidney function. We relied on van-
comycin CL as the benchmark for drug clear-
ance because it is primarily eliminated




This was a retrospective study conducted
across the Michigan Medicine enterprise. Institu-
tional review board approval was obtained from
the University of Michigan prior to the collec-
tion of any patient data.
Design and Study Population
Data were retrospectively obtained from Data-
Direct, a self-service clinical database developed
and maintained by the University of Michigan.
The query time-frame was a 5-year period
between January 2015 and December 2019. Sub-
ject records were queried if the following criteria
were satisfied: (i) patients greater than 18 years
of age, (ii) therapy with intravenous vancomycin
during the study period, and (iii) measurement
of vancomycin concentrations during the course
of therapy. Data queried included patient demo-
graphics, intravenous vancomycin drug orders
and administration times, and laboratory infor-
mation. Data were password protected and
stored on a secure platform maintained by the
university. Data manipulation was accomplished
using the Python programming language and
environment (Python Software Foundation,
Wilmington, DE). Subjects were excluded if they
met any of the following criteria: (i) incomplete
or missing vancomycin dosing or concentration-
time information, (ii) lack of documentation or
non-physiologically plausible height and/or
weight, and (iii) renal replacement therapy (in-
cluding hemodialysis and continuous renal
replacement therapy).
Descriptive Group Stratification
Previous studies have demonstrated varying
levels of performance of eCrCL formulas when
the serum creatinine is rising versus declin-
ing.19, 20 As a consequence, we categorized
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patients in groups to inform the generalizability
of our findings. The four groups were: (i) Stable,
if the Scr on admission (admScr) was within
20% of the minimum recorded SCr (minSCr)
and the maximum recorded Scr (maxScr) was
< 1.5-fold of the minSCr; (ii) Declining, if the
admSCr was ≥ 1.5-fold of the minSCr and the
admScr was within 20% of maxSCr; (iii) Rising,
if the maxScr was ≥ 1.5-fold of the admSCr and
admScr was within 20% of the minSCr; and (iv)
Mixed, individuals with a mixture of stable, ris-
ing, and declining profiles. These definitions
were based on expected variations of SCr and
the Acute Kidney Injury Network criteria for
staging SCr changes.21
Kidney Function Estimates
Alternative body size scalars including IBW,
adjusted body weight (adjBW), and BSA using
Mosteller’s adaptation were computed as previ-
ously described.22 We calculated eCrCL using
the CG equation with total body weight (TBW),
IBW, adjBW, and a dosing weight (DW).7 The
DW was based on the principle for use of IBW
or TBW if TBW < IBW or adjBW if
TBW > 1.25 9 IBW. The eCrCL was also esti-
mated using the Jelliffe equation, Chiou equa-
tion, and the Chen equation.11–13 The eGFR was
estimated using the Modification of Diet in
Renal Disease (MDRD) and Chronic Kidney Dis-
ease Epidemiology Collaboration (CKD-EPI)
equations.4, 5 The CKD-EPI equation served as
the baseline estimate for the Chen equation.
Given that these equations generate estimates of
kidney function in either ml/minute or BSA-in-
dexed as ml/minute/1.73 m2 (denoted as Equa-
tionBSA), we transformed each estimate into both
units for all equations. In total, we evaluated 9
equations (18 estimates) for kidney function.
Pharmacokinetic and Statistical Analyses
Pharmacokinetic analyses were performed
using Monolix2019R2, and Sycomore2019R2
(Monolix Suite2019R2, Antony, France: Lixoft
SAS, 2019). For population PK analysis, the
stochastic approximation expectation maximiza-
tion (SAEM) algorithm was used within Mono-
lix2019R2 and individual vancomycin dosing
and concentration time data. The base model
was a 1-compartment, zero order input and lin-
ear clearance parameterized model structure was
selected given the common clinical application
of this model and reliance on primarily trough
sampled data. The initial volume of distribution
(Vd) was based on 0.7 L/kg and fixed to the
median weight but included random effects for
estimation of inter-individual variability (IIV).
The base model was subsequently modified by
testing each kidney function estimate as a
covariate of CL. Parameters were estimated
based on a log-normal distribution. This was
tested as a time-invariant covariate, which fixes
the kidney function estimate to the first esti-
mated value for each subject and as a time-vary-
ing covariate that tests the covariate as a
regressor function. This regressor function was
set as a simple linear model, typical of the cur-
rent practice of transforming eCrCL to an esti-
mate of vancomycin CL. Model discrimination
was based on the Akaike Information Criterion
(AIC), goodness of fit plots, and changes to the
residual standard error between models. Models
were ranked based on the greatest to smallest
change in AIC relative to the base model. Model
comparisons were performed using Syco-
more2019R2 within the Monolix suite. Non-
parametric distribution error checks were per-
formed with each model run through an efficient
pipeline process within Monolix2019R2.
Descriptive statistical analyses and graphs were
produced using Stata version 16 (StataCorp
LLC, College Station, TX).
Results
Study Population
A total of 2640 adult patients were identified
based on the inclusion and exclusion criteria.
Table 1 summarizes the population demograph-
ics, body size profile for the entire population as
well as by SCr descriptive groups. The majority
of patients were male, and the race distribution
was 81% white and 13.5% black, which is con-
sistent with the demography of Michigan. The
median [min, max] age was 62 [18, 103] years;
75%, 25%, and 7% of the population were over
the ages of 50, 70, and 80 years, respectively.
The average height was approximately 172 cm
with a range of approximately 122–213 cm. The
median [min, max] weight was 95 [38, 298] kg
with 35% of the population ≥ 100 kg. The med-
ian [min, max] body mass index (BMI) was 30.0
[16.5, 99.2] kg/m2, 50.1% met the definition of
obesity (≥ 30 kg/m2), and 15.5% met the defini-
tion of morbid obesity (≥ 40 kg/m2). The esti-
mated kidney function was reported based on
eCrCL and eGFR using the CG_DW and CKD-
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EPI equations from the admission SCr. The med-
ian [min, max] eGFR was 51 [8, 209] ml/min-
ute/1.73 m2, and 18%, 23%, 17%, 19%, 19%,
and 4% of the population met the incremental
CKD staging definitions of > 90, 60–89, 45–59,
30–44, 15–29, and < 15 ml/minute/1.73 m2,
respectively, based on admission SCr. Figure 1
illustrates the fractional change in SCr over time
based on stable, declining, rising, and mixed
group categorizations. When considering only
patients categorized as having stable SCr
(n=1489), 61% met the definition of Stage 3a
CKD or higher (<60 ml/min/1.73 m2) compara-
ble to a rate of 59% when considering the entire
population without this stability categorization.
Observed Concentration Profile
A total of 6628 vancomycin concentrations
were measured and included in the analyses
with a median [5th, 95th percentile] of 2 [1, 7]
samples per patient. The mean (SD) initial dose
was 1264 (323) mg or 14 (3.9) mg/kg. Patients
were on multiple dosing regimens. Therefore,
Figure 2 includes the distribution of concentra-
tions for patients managed with every 12-hour,
every 24-hour, every 48-hour, and every 72-hour
regimens. Figure 2 illustrates the measured van-
comycin concentration against the time since
last dose. As shown, the majority of concentra-
tions collected were > 4 hours from dosing and
so represent mid-point and trough measure-
ments.
Pharmacokinetic Analysis
The median [IQR] Vd and CL was 73.2 [60.5,
98.2] L and 0.59 [0.44, 0.85] L/hour for the
base model. A two-compartment model structure
was also evaluated but did not improve upon
the model fit and had a higher AIC. Table 2 pro-
vides a summary of the AIC values for the base
model (covariate unstructured model) along
with the models that incorporated kidney func-
tion estimates. As shown, the time-varying mod-
els of kidney function had lower AIC values
with a median [min, max] difference of 158
[99, 196] points. Table 2 is organized by
highest to lowest reduction in AIC relative to
the base model. Kidney function estimates that
were not indexed to BSA performed better than
those indexed to BSA at 1.73 m2. The Chen
model and Chiou model performed better than
all other tested models under both time-varying
and time-invariant conditions. Overall, the Chen
method applied as a time-varying covariate had
the lowest AIC value of all the tested models. To
ensure that this rank order was not altered in
stable versus unstable patients, we tested this as
a binary covariate. The previous rank order was
maintained and the AICs for the Chen and
Chiou models were 50,198 and 50,213, confirm-
ing that the Chen model was the best ranked
model. The stability status of any given patient
is not consistently knowable a priori and so this
stability factor was not incorporated into the
final model. Bootstrap analysis with 1000




Total (n=2640)Declining (n=511) Rising (n=460) Mixed (n=180)
Gender (male) 63% 59% 63% 56% 62%
Race
White 81.8% 80.4% 81.7% 75.6% 81.1%
Black 13.0% 14.5% 12.6% 17.2% 13.5%
Other 5.2% 5.1% 5.7% 7.2% 5.4%
Age (yrs) 61 (16) 58 (15) 58 (16) 56 (17) 59 (16)
Height (cm) 172 (11) 171 (11) 172 (11) 172 (11) 172 (11)
Weight (kg) 94.0 (28.1) 93.4 (28.3) 94.2 (25.9) 94.0 (33.2) 93.9 (28.1)
BMI (kg/m2) 31.7 (8.8) 31.7 (8.9) 31.9 (8.5) 32.0 (11.4) 31.7 (9.0)
BSA (m2) 2.10 (0.34) 2.09 (0.34) 2.10 (0.31) 2.09 (0.37) 2.10 (0.34)
SCr (mg/dl) 1.65 (0.96) 1.92 (0.92) 1.15 (0.57) 1.48 (0.92) 1.60 (0.92)
BUN (mg/dl) 36 (23) 44 (26) 26 (16) 33 (21) 36 (23)
Albumin (g/L) 3.2 (0.6) 3.1 (0.7) 3.1 (0.7) 3.2 (0.7) 3.2 (0.6)
eCrCL (ml/min) 63 (39) 52 (31) 88 (53) 74 (44) 66 (43)
eGFR (ml/min/1.73 m2) 56 (31) 46 (27) 75 (33) 64 (33) 58 (32)
Mean (standard deviation) or percent values at admission.
BMI = body mass index; BSA = body surface area; BUN = blood urea nitrogen; eCrCL = estimated creatinine clearance using Cockcroft-Gault
equation with dosing weight; eGFR = estimate glomerular filtration rate using the chronic kidney disease epidemiology equation;
SCr = serum creatinine.
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bootstrap replicates to obtain 95% confidence
intervals for all pharmacokinetic parameters are
included in Table 3. The final model provided
reasonable internal validity based on NPDE anal-
ysis that showed a majority of values within a
normal distribution ranging from 2 to 2.
Discussion
Drug dosing based on kidney function is per-
formed routinely in hospitalized patients often
using eCrCL based on the CG equation.3 Elec-
tronic health records (EHR) automatically report
the eGFR using the MDRD or CKD-EPI equa-
tion that is also based on SCr.6 Although there
is much controversy on the selection and inter-
changeability of these equations for drug dosing,
an often overlooked issue is their applicability in
patients who are acutely ill. Homeostasis in the
generation and elimination of creatinine is
required for the use of a single point measure-
ment to be translated into eCrCL or eGFR,
which is not consistently the case.10 We have
previously demonstrated in a large cohort of
hospitalized patients with infections that AKI is
present on admission in 17.5% of cases, and in
over half of these cases, kidney function
improves.23 Similarly, the current investigation
511 (19.3%) had elevated SCr that declined dur-
ing the admission. Overall, in this cohort of van-
comycin-treated patients, 43.6% of patients were
classified as having unstable kidney function,
implying that commonly applied equations that
use single-point measurement of SCr may be less
reliable for drug dosing.
Two researchers10, 11 pioneered the first
approach to estimation of kidney function in
acutely ill and unstable patients. The underlying
principles behind this equation was on empirical
grounds that required an estimate of creatinine
production based on age, gender, and ideal body
weight (to reflect skeletal muscle mass).10, 11
These estimates for creatinine production were
based on the data and a Vd estimate of 0.6 L/
kg.24 More contemporary estimates of creatinine
production also rely on age, gender, and skeletal
Figure 1. Local polynomial fitted with 95% confidence interval (CI) plot of the fractional change in serum creatinine
(weighted to the minimum observed serum creatinine) over time.
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muscle mass.25 These principles were later
extended to include a small component of non-
renal clearance of creatinine in patients with
unstable kidney function.12 Modeling and simu-
lation exercises using these approaches have
nicely demonstrated the time lag between
changes in SCr and shifts in kidney function.26
However, forecasting this time lag is not easy to
accomplish in clinical practice as it is dependent
on the baseline SCr and an assumption of con-
stant production that also may not be correct in
acutely ill patients.26 The simplest approach
undertaken by these methods includes a moving
average approach that includes the average of
two sequential SCr measurements and the time
difference between these measurements.10–12
Recently, this approach was extended by incor-
porating a fractional change in eGFR reliant to
the maximum expected change in SCr per day
of 1.5 mg/dl per day.13 Details regarding the
derivation of this formula and practical use are
included in the original publication.13 Recently,
this equation has been applied in practice to
illustrate its potential utility for drug dosing in
patients with AKI.14 Furthermore, extended
covariate models using the CKD-EPI equation in
patients with unstable kidney function have
been explored in population PK models of van-
comycin.15 These developments led us to inter-
rogate current kidney function equations in a
large cohort of patients treated with van-
comycin.
We specifically sought to compare eGFR and
eCrCL as covariates of drug clearance in order
to rank order the performance of these equations
in patients with stable and unstable kidney func-
tion. These models were constructed as time-in-
variant implying use of the initial measurement
for the entire time-course. We also tested a
time-varying covariate structure and demon-
strated that this extension improved the model
fit. Our large cohort of subjects supports gener-
alizability of our findings through inclusion of a
wide range of age (18–103 yrs), weight
Figure 2. Vancomycin concentrations over the time since last dose stratified by (A) every 12 hr regimen (B) every 24 hr
regimen (C) every 48 hr regimen, and (D) every 72 hr regimen.
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(38–103 kg), and BMI (16.5–99.2 kg/m2). These
contemporary age and body size distributions far
exceed the populations used to derive prior for-
mulas for kidney function in unstable patients.
Despite the largely empiric grounds for their
construct, the Chiou equation and Jelliffe equa-
tion also performed well in this cohort of
patients. The Chen equation ultimately was asso-
ciated with the lowest AIC and selected as the
final model. Paramount to this rank order was
our demonstration that estimates of kidney
function in absolute units performed better than
those indexed to BSA. The underlying limitation
and source of error with this indexation has
been reviewed.27
Our findings have important implications for
practice given that kidney function is routinely
estimated for drug dosing.3 We selected the
CKD-EPI equation as the baseline estimate for
the Chen formula for multiple reasons: (i) a
prior study has demonstrated this equation to be
better than others tested for estimation of van-
comycin CL14; (ii) eGFR is automatically out-
putted in the EHR when SCr is measured and is
based on the MDRD or CKD-EPI equation; (iii)
the CKD-EPI equation permits estimation across
the kidney function spectrum, while the accu-
racy of the MDRD equation is best for patients
with an eGFR < 60 ml/minute/1.73 m2; (iv) a
small modification to the existing EHR output
would be needed with use of the Chen formula
allowing for improved implementation of future
automated dosing protocols; and (v) harmoniza-
tion of future drug-dosing labels is needed given
current inconsistencies.15,28 Undoubtedly, addi-
tional studies are necessary to overcome the lim-
itations of our current analysis before broad
application. Increasing measurement of both a
peak and trough concentration when dosing
vancomycin will allow for reevaluation of our
findings by not fixing Vd.
18 Although multiple
Table 2. Summary of the Akaike Information Criterion (AIC) for each of the Tested Kidney Function Estimated and Com-
pared to the Baseline Model by Largest to Smallest Change in AIC (DAIC)
Time-Invariant Time-Varying
Model AIC DAIC Model AIC DAIC
Base model 50,530 Base model 50,530
Chiou (ml/min) 50,388 142 Chen (ml/min) 50,209 321
Chen (ml/min) 50,405 125 Chiou (ml/min) 50,222 308
CG_TBW (ml/min) 50,415 115 CG_TBW (ml/min) 50,236 294
Jelliffe (ml/min) 50,424 106 Jelliffe (ml/min) 50,250 280
CKD-EPI (ml/min) 50,430 100 CG_DWBSA (ml/min/1.73 m2) 50,352 178
CG_DW (ml/min) 50,434 96 CKD-EPI (ml/min) 50,255 275
ChiouBSA (ml/min/1.73 m
2) 50,438 92 MDRD (ml/min) 50,265 265
CG_AdjBW (ml/min) 50,439 91 CG_DW (ml/min) 50,266 264
MDRD (ml/min) 50,454 76 CG_AdjBW (ml/min) 50,276 254
CG_TBWBSA (ml/min/1.73 m
2) 50,466 64 Chiou (ml/min) 50,297 233
ChenBSA (ml/min/1.73 m
2) 50,467 63 Chen (ml/min) 50,298 232
CG_IBW (ml/min) 50,473 57 CG_TBWBSA (ml/min/1.73 m2) 50,314 216
JelliffeBSA (ml/min/1.73 m
2) 50,477 53 JelliffeBSA (ml/min/1.73 m2) 50,326 204
CG_DWBSA (ml/min/1.73 m
2) 50,489 41 CG_IBW (ml/min) 50,330 200
CKD-EPIBSA (ml/min/1.73 m
2) 50,491 39 CKD-EPIBSA (ml/min/1.73 m2) 50,342 188
CG_AdjBWBSA (ml/min/1.73 m
2) 50,493 37 MDRDBSA (ml/min/1.73 m2) 50,357 173
MDRDBSA (ml/min/1.73 m
2) 50,502 28 CG_AdjBWBSA (ml/min/1.73 m2) 50,360 170
CG_IBWBSA (ml/min/1.73 m
2) 50,515 15 CG_IBWBSA (ml/min/1.73 m2) 50,416 114
Models labeled by name of author, Chiou, Chen, Jelliffe. A subscript of BSA to denote body surface area indexed values.
CG_AdjBW, Cockcroft-Gault equation using adjusted body weight; CG_DW, Cockcroft-Gault equation using dosing weight; CG_IBW, Cock-
croft-Gault equation using ideal body weight; CG_TBW, Cockcroft-Gault equation using total body weight; CKD-EPI, chronic kidney disease
epidemiology equation; MDRD, modification of diet in renal disease equation.
Table 3. Parameter Estimates of the Final Model and
Bootstrap Analysis of Parameter Estimates
Parameter Final Model
Bootstrap of Final Model
Estimate 95% CI
Vd (L) 66.4 (fixed)
CL (L/h)
h1 1.03 1.03 1.02–1.05
h2 0.737 0.758 0.657–0.863
h3 1.63 1.69 1.83 to 1.57
IIV
h1 1.82 1.80 1.64–1.96
h2 1.24 1.21 1.12–1.30
h3 1.32 1.28 1.18–1.36
Residual variability
Additional 0.76 0.76 0.73–0.79
CL = clearance; Vd = volume of distribution; For the final model,
CL = exp(h1 + h2 9 (eGFR/100))  h3, where eGFR is the esti-
mated glomerular filtration rate using the Chen equation in ml/
min.13
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samples were measured in patients especially
among those with extended dosing intervals, few
samples were collected 2–4 hours post infusion.
This was our primary reason for having fixed
but random effects for Vd. Our findings for kid-
ney function performance may or may not
extend to other drugs that are dose adjusted for
renal impairment or recovery and requires fur-
ther study before broad implementation. Finally,
our intent was not to develop a new model of
vancomycin CL but rather to compare existing
renal function models as covariates of drug CL.
Therapeutic drug monitoring is widely available
for vancomycin and will be the more reliable
approach to dosing this agent in patients with
unstable kidney function.
Conclusion
A kinetic eGFR estimate based on the Chen
equation was ranked above other tested models
for estimation of vancomycin CL in patients
with stable and unstable kidney function. Use of
a time-varying covariate structure was superior
to a time-invariant one. Estimates of eGFR per-
form better in absolute rather than BSA indexed
values when estimating drug CL.
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